{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:52:22Z","timestamp":1789080742228,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100031015","name":"Hospital Clinic of Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>(1,3)-\u03b2-D-Glucan (BDG) testing with Fungitell\u00ae assay has been shown to support antifungal stewardship by shortening empirical antifungal therapy in critically ill patients; however, data on Wako\u00ae assay are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, non-randomized study conducted over 15\u2005months in a tertiary care hospital. Critically ill patients receiving empirical echinocandin therapy with a BDG measurement within 48\u2005h were included. Patients were stratified by Candida score (low risk &amp;lt;3, high risk \u22653) and initial BDG result and followed for 30\u2005days after discontinuation or death. The primary endpoint was early echinocandin discontinuation and total antifungal duration. Secondary endpoints included mortality, invasive candidiasis (IC) within 30\u2005days, length of stay and antifungal consumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety patients were included. Among low-risk patients (n\u200a=\u200a27), 81.5% (22\/27) had negative BDG; antifungal therapy was discontinued early in 77.3% (17\/22) of BDG-negative versus 20% (1\/5) of BDG-positive cases, with no IC diagnosed. Among high-risk patients (n\u200a=\u200a63), 58.7% (37\/63) had negative BDG; therapy was discontinued in 75.7% (28\/37). In high-risk patients with positive BDG (n\u200a=\u200a26), there were 3 IC (11.5%); in all cases, the antifungal was maintained. Early discontinuation was more frequent in BDG-negative patients (77.2% versus 19.2%; P\u200a&amp;lt;\u200a0.001), resulting in shorter echinocandin (2 versus 4\u2005days; P\u200a=\u200a0.004) and total antifungal therapy (3 versus 8\u2005days;P\u200a&amp;lt;\u200a0.001), without differences in mortality or subsequent IC. Echinocandin costs decreased by \u223c50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BDG-guided management using Wako\u00ae assay increased early antifungal discontinuation and reduced echinocandin exposure. BDG should be used cautiously as an adjunctive tool, particularly in high-risk patients, due to potential false negatives.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag226","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:55:42Z","timestamp":1783684542000},"source":"Crossref","is-referenced-by-count":1,"title":["Biomarker-driven strategy for early discontinuation of empirical antifungal treatment in critically ill patients: the role of (1-3)-\u03b2-\n                    <scp>D-<\/scp>\n                    glucan using Wako\u00ae test"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-670X","authenticated-orcid":false,"given":"M","family":"Albanell-Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Division of Medicines, Pharmacy Service, Hospital Clinic of Barcelona, Universitat de Barcelona , Barcelona ,","place":["Spain"]},{"name":"Department of Physiological Science, School of Medicine, Universitat de Barcelona, L'Hospitalet de Llobregat , Barcelona ,","place":["Spain"]},{"name":"Institut D'investigaci\u00f3 Biom\u00e8dica August Pi I Sunyer (IDIBAPS) , Barcelona ,","place":["Spain"]},{"name":"Faculty of Medicine, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9153-6956","authenticated-orcid":false,"given":"M","family":"Tuset","sequence":"additional","affiliation":[{"name":"Division of Medicines, Pharmacy Service, Hospital Clinic of Barcelona, Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Vergara","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Clinic of Barcelona, CDB, Universitat de Barcelona , Barcelona ,","place":["Spain"]},{"name":"Institute of Global Health (ISGlobal) , Barcelona ,","place":["Spain"]},{"name":"CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Clinic of Barcelona, CDB, Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Barrantes-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Division of Medicines, Pharmacy Service, Hospital Clinic of Barcelona, Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bodro","sequence":"additional","affiliation":[{"name":"Institut D'investigaci\u00f3 Biom\u00e8dica August Pi I Sunyer (IDIBAPS) , Barcelona ,","place":["Spain"]},{"name":"Faculty of Medicine, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"A","family":"Soriano","sequence":"additional","affiliation":[{"name":"Institut D'investigaci\u00f3 Biom\u00e8dica August Pi I Sunyer (IDIBAPS) , Barcelona ,","place":["Spain"]},{"name":"Faculty of Medicine, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hern\u00e1ndez-Meneses","sequence":"additional","affiliation":[{"name":"Institut D'investigaci\u00f3 Biom\u00e8dica August Pi I Sunyer (IDIBAPS) , Barcelona ,","place":["Spain"]},{"name":"Faculty of Medicine, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Mu\u00f1oz-Rojas","sequence":"additional","affiliation":[{"name":"Anesthesiology Department, Hospital Clinic de Barcelona, Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Herrera","sequence":"additional","affiliation":[{"name":"Institut D'investigaci\u00f3 Biom\u00e8dica August Pi I Sunyer (IDIBAPS) , Barcelona ,","place":["Spain"]},{"name":"Faculty of Medicine, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"Department of Infectious Diseases, Hospital Clinic of Barcelona, Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072415101083100_dkag226-B1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00134-014-3310-z","article-title":"A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality","volume":"40","author":"Bassetti","year":"2014","journal-title":"Intensive Care Med"},{"key":"2026072415101083100_dkag226-B2","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/jac\/dkw112","article-title":"(1,3)-\u03b2-D-glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study","volume":"71","author":"Posteraro","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026072415101083100_dkag226-B3","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/jac\/dkad139","article-title":"Invasive candidiasis: current clinical challenges and unmet needs in adult populations","volume":"78","author":"Soriano","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026072415101083100_dkag226-B4","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s00134-025-08151-1","article-title":"Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy","volume":"51","author":"Martin-Loeches","year":"2025","journal-title":"Intensive Care Med"},{"key":"2026072415101083100_dkag226-B5","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac055","article-title":"A multisite evaluation of antifungal use in critical care: implications for antifungal stewardship","volume":"4","author":"Logan","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2026072415101083100_dkag226-B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13613-015-0103-7","article-title":"Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study","volume":"6","author":"Leroy","year":"2016","journal-title":"Ann Intensive Care"},{"key":"2026072415101083100_dkag226-B7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/medicina57070656","article-title":"Post-prescription audit plus Beta-D-glucan assessment decrease echinocandin use in people with suspected invasive candidiasis","volume":"57","author":"Murri","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2026072415101083100_dkag226-B8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00134-023-07034-7","article-title":"Antifungal stewardship in critically ill patients","volume":"49","author":"De Pascale","year":"2023","journal-title":"Intensive Care Med"},{"issue":"Suppl 6","key":"2026072415101083100_dkag226-B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/1469-0691.12622","article-title":"Antifungal stewardship in invasive Candida infections","volume":"20","author":"Ruhnke","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"suppl_1","key":"2026072415101083100_dkag226-B10","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/jac\/dkx444","article-title":"Changes in the epidemiological landscape of invasive candidiasis","volume":"73","author":"Lamoth","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026072415101083100_dkag226-B11","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/cid\/cit006","article-title":"Finding the \u201cmissing 50%\u201d of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care","volume":"56","author":"Clancy","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026072415101083100_dkag226-B12","doi-asserted-by":"publisher","first-page":"R249","DOI":"10.1186\/cc10507","article-title":"Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1\u21923)-\u03b2-D-glucan assay, Candida score, and colonization index","volume":"15","author":"Posteraro","year":"2011","journal-title":"Crit Care"},{"key":"2026072415101083100_dkag226-B13","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/cid\/ciq206","article-title":"B-Glucan assay for the diagnosis of invasive fungal infections: a meta-analysis","volume":"52","author":"Karageorgopoulos","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026072415101083100_dkag226-B14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jmii.2014.06.009","article-title":"A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-\u03b2-d-glucan for invasive fungal infection: focus on cutoff levels","volume":"48","author":"He","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"2026072415101083100_dkag226-B15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10096-014-2239-z","article-title":"Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit","volume":"34","author":"Lo Cascio","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026072415101083100_dkag226-B16","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/jac\/dkw188","article-title":"Discontinuation of empirical antifungal therapy in ICU patients using 1,3-\u03b2-D-glucan","volume":"71","author":"Nucci","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026072415101083100_dkag226-B17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s00134-014-3281-0","article-title":"What\u2019s new in the clinical and diagnostic management of invasive candidiasis in critically ill patients","volume":"40","author":"Le\u00f3n","year":"2014","journal-title":"Intensive Care Med"},{"key":"2026072415101083100_dkag226-B18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026072415101083100_dkag226-B19","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026072415101083100_dkag226-B20","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1007\/s00134-017-4932-8","article-title":"Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial","volume":"43","author":"Rouz\u00e9","year":"2017","journal-title":"Intensive Care Med"},{"key":"2026072415101083100_dkag226-B21","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00725-23","article-title":"\u03b2-(1\u21923)-D-glucan- and mannan-guided early termination of antifungal therapy in ICU patients: a randomized controlled study","volume":"67","author":"Erb","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026072415101083100_dkag226-B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236095","article-title":"Comparative performance evaluation of Wako \u03b2-glucan test and Fungitell assay for the diagnosis of invasive fungal diseases","volume":"15","author":"De Carolis","year":"2020","journal-title":"PLoS One"},{"key":"2026072415101083100_dkag226-B23","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00464-18","article-title":"Comparative analysis of the Wako \u03b2-glucan test and the Fungitell assay for diagnosis of candidemia and Pneumocystis jirovecii pneumonia","volume":"56","author":"Friedrich","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2026072415101083100_dkag226-B24","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1097\/CCM.0b013e31819daa14","article-title":"Usefulness of the \u201cCandida score\u201d for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study","volume":"37","author":"Le\u00f3n","year":"2009","journal-title":"Crit Care Med"},{"issue":"Suppl_2","key":"2026072415101083100_dkag226-B25","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1093\/cid\/ciaa1751","article-title":"EORTC\/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group","volume":"72","author":"Bassetti","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026072415101083100_dkag226-B26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13054-020-03265-y","article-title":"(1,3)-\u03b2-D-glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial","volume":"24","author":"De Pascale","year":"2020","journal-title":"Crit Care"},{"key":"2026072415101083100_dkag226-B27","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01691-22","article-title":"Comparison of three \u03b2-glucan tests for the diagnosis of invasive candidiasis in intensive care units","volume":"61","author":"Kritikos","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2026072415101083100_dkag226-B28","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/cid\/ciz555","article-title":"Clinical relevance and prognostic value of persistently negative (1,3)-\u03b2-D-glucan in adults with candidemia: a 5-year experience in a tertiary hospital","volume":"70","author":"Agnelli","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"S7","key":"2026072415101083100_dkag226-B29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/imj.15586","article-title":"Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021","volume":"51","author":"Khanina","year":"2021","journal-title":"Intern Med J"},{"key":"2026072415101083100_dkag226-B30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jgar.2019.05.030","article-title":"Antifungal stewardship with an emphasis on candidaemia","volume":"19","author":"Capoor","year":"2019","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/8\/dkag226\/69969173\/dkag226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/8\/dkag226\/69969173\/dkag226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:10:19Z","timestamp":1784920219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag226\/8741630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag226","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dkag226"}}